Amphista Therapeutics Limited
Registered name: AMPHISTA THERAPEUTICS LIMITED
Amphista Therapeutics Limited made £33.9m revenue and £19.8m profit in the year to 31 Dec 2024.
Amphista Therapeutics Limited’s revenue grew 217% to £33.9m in the year to 31 Dec 2024, with £19.8m profit and 56 employees. The company is classified under “research and experimental development on biotechnology” and is based in Cambridge; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Cambridge, East of England
- Age
- 8 yrs · since 2017
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £10.7m | £33.9m |
| Cost of sales | −£2.6m | −£1.3m |
| Gross profit | £8.1m | £32.6m |
| Operating profit | −£15.1m | £12m |
| Profit before tax | −£13.1m | £19.8m |
| Profit after tax | −£9m | £19.8m |
| Profit (best available) | −£9m | £19.8m |
| Employees (average) | 64 | 56 |
| Ratios | ||
| Profit margin | −83.8% | 58.5% |
| Gross margin | 75.3% | 96.2% |
| Revenue per employee | £167k | £606k |
| Profit per employee | −£140k | £354k |
| Growth (year on year) | ||
| Revenue growth | — | ▲217% |
| Headcount growth | — | ▼12.5% |
| Balance sheet — indirect signals, not revenue | ||
| Net assets | — | — |
| Source | Accounts · bulk data Jan 2026 | Accounts · bulk data Jul 2026 |
How the business works
- Profit margin
- 58.5%
- Profit ÷ revenue.
- Gross margin
- 96.2%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £606k
- Revenue ÷ average employees.
- Profit per employee
- £354k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- ▼13%
- Now 56
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Novogene (UK) Company LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £38.2m
- Profit
- £2.8m
- Staff
- 68
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Novo Nordisk Research and Development UK LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £52.2m
- Profit
- £2.5m
- Staff
- 181
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
Sources
Latest figures from accounts for the year to 31 Dec 2024 (profit £19.8m), from the Companies House accounts bulk data published Jul 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.